Dr. Gary Myers is Chief of the Clinical Chemistry Branch, Centers for Disease Control and Prevention. He also serves as the Scientific Director, WHO Collaborating Center for Reference and Research in Blood Lipids at CDC. Dr. Myers received his PhD in analytical chemistry from the Georgia Institute of Technology, Atlanta, GA in 1975.
In his 30+ year career at CDC he has focused on improving laboratory measurements of biochemical markers used to assess chronic disease risk, with particular emphasis on cardiovascular disease. Dr. Myers has published more than 80 articles, book chapters and editorials.
Dr. Myers has served the AACC at all levels of the organization. He is currently serving as AACC President. He was the recipient of the 2006 AACC award for Outstanding Contributions through Service to the Profession of Clinical Chemistry. Dr. Myers is also a Fellow in the National Academy of Clinical Biochemistry. At the national level he served as the Chair of the 2002 Annual Meeting Organizing Committee. He was Volunteer Coordinator for the 1997 national meeting and Roundtable Coordinator for the 1999 national meeting. He served as Chair of the 2006 Arnold O. Beckman Conference. Dr. Myers served on numerous national committees including, Standards Committee, Glycated Hemoglobin Standardization Subcommittee, Nominating Committee, Membership Committee, as an ex-officio member of the Meetings Management Group, and Board of Directors.
In addition to his service to the AACC, Dr. Myers is also involved with various national and international organizations and committees dealing with laboratory measurement issues. He is a member of the National Kidney Disease Education Program’s Laboratory Working Group. He is also a member of the American Diabetes Association’s Insulin Standardization Working Group. He served as a consultant for lipid measurement issues to the Chemistry Resource Committee of the College of American Pathologists.
Dr. Myers is active in the Clinical and Laboratory Standards Institute (CLSI) where he served two terms on the Board of Directors and as chair of the Global Advisory Committee.